Immunology CRO Services for Biotech and Pharmaceutical Companies

Evestia Clinical helps biotechnology and pharmaceutical companies advance immunology programs through integrated scientific expertise, biomarker-driven development and regulatory support from Phase I to global registration.

Our Approach

Immunology Development Built Around Biotech Companies

Immunology development rewards biomarker-driven science, biologics expertise and precision medicine thinking, delivered through integrated multidisciplinary collaboration across scientific, clinical and regulatory functions. Consistent senior scientific leadership throughout program delivery is central to this approach.

Evestia Clinical works as an integrated scientific partner throughout clinical development, providing expertise across Clinical Operations, Medical Affairs, Regulatory Affairs, Biostatistics and Clinical Data Management, through our Full-Service CRO model or embedded specialists via FSP Solutions.

Experienced Immunology Medical Specialists

Direct access to scientists with hands-on Phase I–IV & Post-Marketing experience across autoimmune disease, immuno-oncology, biologics and advanced therapies.

Senior Scientific Leadership

Consistent senior scientific leadership throughout program delivery, supporting informed decisions, clear communication and program confidence at every milestone.

Integrated Full-Service Expertise

Clinical Operations, Medical Affairs, Regulatory Affairs, Biostatistics, Medical Writing and Pharmacokinetics working as one coordinated immunology team.

Flexible FSP and CRO Models

Full-Service CRO and FSP Solutions providing scalable expertise aligned with program requirements and evolution.

Track Record

Immunology Expertise at a Glance

These figures reflect direct program experience across the full breadth of immune-mediated development, informing every biomarker, regulatory and operational decision Evestia Clinical makes.

60+

Immunology Studies Supported

Across diverse immune-mediated conditions

42%

Team with Direct Immunology Expertise

Specialist immunology experience

Adult & Pediatric

Development Experience

Supporting diverse patient populations

Immuno-Oncology

Specialist Expertise

Immunology and oncology combined

Unique Challenges

Scientific Considerations in Immunology Development

Biomarker integration, validated assay platforms, immunogenicity assessment and companion diagnostic strategies shape the design and delivery of modern immunology programs. Precision medicine approaches and heterogeneous patient populations require integrated scientific planning across clinical, regulatory and statistical functions from the outset.

Long-term immune monitoring adds depth to biologics and ATMP programs, while combination therapy development calls for specialist safety assessment across treatment combinations. Our Global CRO capabilities support programs across Phase I, Phase II and Phase III. Key program considerations include:

Complex disease biology
Biomarker-driven development
Precision medicine approaches
Autoimmune disease variability
Long-term safety considerations
Specialist investigator networks
Evolving regulatory requirements
Novel treatment modalities
Heterogeneous patient populations
Biomarker validation strategies
Long-term immune monitoring
Combination therapy complexity
Novel biologics development
ATMP regulatory frameworks
Complex endpoint selection
Immune pathway variability
Overview

Developing Therapies for Immune-Mediated Diseases Requires More Than Operational Delivery

Successful immunology development depends on disease-specific scientific planning, biomarker strategy and integrated multidisciplinary expertise from protocol design through regulatory submission. Each immune-mediated indication brings distinct scientific and operational requirements that benefit from therapeutic understanding embedded throughout the program.

Immunology sits at the convergence of precision medicine, biologics, advanced therapies and immuno-oncology. Many autoimmune conditions are also driven by dysregulated inflammatory pathways, making integrated Inflammation clinical trial expertise directly relevant. Clinical Trial Management, Medical Affairs, Clinical Data Management, Biostatistics and Regulatory Affairs work within one coordinated team throughout every program.

Autoimmune Disease

Supporting Complex Autoimmune Programs With Confidence

Biomarker-guided patient stratification, companion diagnostics and personalized treatment strategies are reshaping autoimmune study design. Clinical development teams that integrate these approaches from the outset generate stronger proof-of-concept data and more compelling regulatory evidence.

Heterogeneous populations, long-term safety requirements and evolving treatment standards bring increasing scientific and operational complexity. Many autoimmune conditions involve dysregulated inflammatory pathways, making integrated Inflammation clinical trial expertise directly relevant. Autoimmune disease experience includes programs across:

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus (SLE)
  • Psoriasis and Psoriatic Arthritis
  • Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Immuno-Oncology

Integrated Expertise Across Advanced Immune Therapies

Immuno-oncology programs involve adaptive designs, combination therapy strategies and biomarker-driven patient selection that benefit from integrated Oncology and Immunology expertise delivered within one multidisciplinary scientific team.

Combining Immunology and Oncology CRO capabilities, Evestia Clinical supports checkpoint inhibitors, cancer immunotherapies and immune-based combination treatments through integrated scientific, operational and regulatory support. Tumor immune microenvironment assessment, immune response monitoring and combination safety management are embedded within every immuno-oncology program.

Services

Our Immunology Clinical Trial Services

Integrated scientific collaboration, coordinated operational delivery and aligned regulatory support keep biomarker consistency and program quality intact as immunology programs advance. Every service below is delivered within one integrated team, aligned towards the same program outcome.

Clinical Trial Management

Providing program leadership, vendor management and operational oversight throughout the full immunology study lifecycle from initiation through close-out.

Learn more

Clinical Operations

Integrated clinical operations support across immunology programs, coordinating investigators, sites, vendors and study activities across complex multi-site studies.

Learn more

Clinical Monitoring

Supporting investigator sites through specialist monitoring, compliance oversight and quality management across immunology and autoimmune disease programs.

Learn more

Clinical Site Management

Helping sponsors identify and engage high-performing investigator sites with immunology and autoimmune disease expertise for optimal recruitment and data quality.

Learn more

Study Start-Up Services

Accelerating site feasibility, selection and activation to reduce timelines from protocol development to first patient enrolled in immunology studies.

Learn more

Regulatory Affairs

Supporting global regulatory strategies, submissions and health authority interactions for immunology programs including biologics and ATMP development.

Learn more

Clinical Data Management

Managing complex immunology datasets, biomarker data and integrated clinical information with CDISC-compliant outputs for regulatory submissions.

Learn more

Biostatistics

Providing advanced statistical planning, endpoint analysis and submission-ready reporting support for immunology studies with complex designs.

Learn more

Medical Affairs

Learn more

Pharmacovigilance

Delivering comprehensive safety oversight throughout immunology development and post-marketing activities including biologics safety monitoring.

Learn more

Medical Writing

Preparing protocols, investigator brochures, Clinical Study Reports and regulatory documentation for immunology and biologics submissions.

Learn more

Pharmacokinetics

Supporting PK/PD modeling, exposure-response analysis and immunogenicity assessments for biologics and novel immunology therapies.

Learn more

FSP Solutions

Dedicated embedded immunology specialists through our Functional Service Provider model for sponsors requiring flexible specialist resource scaling.

Learn more
Expertise

Expertise Across Immune-Mediated Diseases

Each indication presents distinct scientific, operational and regulatory considerations. Disease-specific knowledge helps shape recruitment strategy, endpoint design and regulatory positioning across immune-mediated programs.

Autoimmune Diseases

Supporting programs targeting immune system dysfunction and chronic autoimmune conditions, from Rheumatoid Arthritis and Lupus to Psoriasis and Inflammatory Bowel Disease. Precision medicine and companion diagnostic strategies are reshaping autoimmune development, requiring sponsors to integrate biomarker-guided patient selection and personalized treatment approaches into program design from the outset.

Inflammatory Disorders

Helping sponsors develop therapies designed to address complex inflammatory pathways and chronic inflammatory disease progression. Immunology and inflammation are closely interconnected, explore our dedicated Inflammation clinical trial expertise.

Inflammation Clinical Trials

Immuno-Oncology

Leveraging expertise at the intersection of oncology and immunology to support innovative cancer immunotherapies, checkpoint inhibitors and immune-based combination treatments, with biomarker-driven patient selection and adaptive trial designs at the core.

Rare Immune Disorders

Combining Immunology and Rare Disease expertise to support therapies targeting underserved rare immune-mediated conditions, including orphan designation support and regulatory incentive strategies.

Rare Disease CRO

Cell & Gene Therapy

Supporting advanced therapies that utilize immune system mechanisms to treat complex immune-mediated diseases, including CAR-T therapies, gene therapies and other ATMPs requiring specialist operational and regulatory frameworks.

Cell & Gene Therapy CRO
Development Lifecycle

Supporting Immunology Programs from Early Development Through Regulatory Submission

Scientific continuity strengthens biomarker consistency, regulatory planning and program quality throughout development. The biomarker decisions made in Phase I shape stratification strategy in Phase II and the evidence framework presented at registration.

Regulatory Affairs and Clinical Trial Management are aligned from the outset, maintaining consistent scientific and regulatory direction from Phase I through Phase II into Phase III registration.

Development Phases

Immunology Development Across Every Phase

Phase I CRO

First-in-human and dose escalation in immunology and biologics, establishing the safety profile and proof-of-mechanism evidence that biomarker strategies and subsequent regulatory positioning depend on.

Learn more
Phase II CRO

Proof of concept, biomarker refinement and efficacy signal evaluation in diverse immune-mediated populations, using adaptive designs and precision medicine approaches to maximize the value of available data.

Learn more
Phase III CRO

Multinational registration programs coordinated across specialist immunology investigator networks, generating submission-ready evidence for health authorities across key global markets.

Learn more
Integrated Expertise

Immunology, Oncology and Cell and Gene Therapy Expertise Combined

Modern immunology sits at the intersection of Oncology CRO, Cell and Gene Therapy, Rare Disease and Inflammation development. Programs targeting orphan immune disorders also benefit from Orphan Drug Development incentive strategies. This integrated experience covers:

  • Immuno-oncology programs
  • Cell and gene therapies
  • Rare immune disease development
  • Precision medicine and biomarker-driven studies
  • Chronic inflammatory disease programs
  • Advanced therapy medicinal products (ATMPs)
  • Immune pathway research
Where Evestia Adds Value

How Evestia Strengthens Immunology Development

Integrated biomarker leadership, collaborative scientific delivery and consistent immunology expertise support program confidence and regulatory success throughout immune-mediated development.

Biomarker-Driven Development

Validated biomarker strategies enable patient stratification, proof-of-mechanism assessment and regulatory evidence enrichment. Integrating biomarker data across Clinical Data Management, Biostatistics and Regulatory Affairs requires a team with the scientific depth to manage these functions as one cohesive program.

Complex Biologics

Monoclonal antibodies, fusion proteins and other biological medicines require specialist expertise in immunogenicity, PK/PD modeling and biologics regulation under FDA, EMA and MHRA guidance, with integrated data management and safety reporting throughout.

Immunogenicity Assessment

Immune responses to biologics and ATMPs affect safety, efficacy and regulatory confidence. Specialist immune monitoring, assay validation and safety reporting planned proactively from the earliest stages of development support confident program progression.

Autoimmune Disease Complexity

Heterogeneous populations, evolving treatment standards and long-term safety requirements characterize autoimmune development. Adaptive operational approaches strengthen study design and program delivery as precision medicine and companion diagnostic integration reshape the therapeutic landscape.

Advanced Therapies

CAR-T therapies and gene-modified immune cells require specialist regulatory frameworks, one-time dosing logistics and long-term immune response monitoring. Integrated immunology and Cell and Gene Therapy expertise creates integrated scientific collaboration across both disciplines.

Scalable Immunology Expertise

As immunology portfolios grow, access to embedded scientific leadership and integrated partnership across biomarker strategy, regulatory affairs and clinical operations becomes a strategic priority. Full-Service CRO and FSP delivery provide the depth and program flexibility needed at each stage.

Why Evestia Clinical

Why Sponsors Choose Evestia Clinical for Immunology Clinical Trials

The immunology CRO a sponsor chooses shapes the scientific quality of every endpoint decision, the strength of every regulatory submission and the confidence with which a program approaches its most important milestones. As a specialist Biotech CRO, Evestia Clinical is structured to provide the expertise, senior access and operational agility that complex immunology programs demand.

Immunology Knowledge Embedded in Every Program

Dedicated immunology teams with direct experience across autoimmune diseases, inflammatory disorders, biologics, immuno-oncology and advanced therapies, providing experienced scientific guidance throughout program delivery.

Meet our team

Supporting Complex Autoimmune Programs With Confidence

Deep operational and scientific experience across Rheumatoid Arthritis, SLE, IBD, Psoriasis and other chronic autoimmune and inflammatory conditions, combined with specialist Inflammation clinical trial expertise and biomarker-guided development capability.

Inflammation Clinical Trials

Integrated Expertise Across Advanced Immune Therapies

Integrated Immunology and Oncology CRO capabilities, combined with Cell and Gene Therapy expertise, supporting sponsors developing checkpoint inhibitors, combination immunotherapies, CAR-T therapies and other advanced immune-based treatments throughout development.

Oncology CRO

Cell and Gene Therapy for Immune-Mediated Disease

Specialist support for ATMPs and advanced immune-based therapies, combining immunology expertise with Cell and Gene Therapy operational knowledge for CAR-T programs, gene therapies and other innovative treatment modalities requiring specialist regulatory and operational frameworks.

Cell and Gene Therapy CRO

A Scientific Partner Built for Biotechnology Companies

Senior-led program delivery, direct communication and integrated scientific collaboration give biotechnology organizations the responsiveness they need to support confident program progression and informed development decisions throughout the lifecycle.

Biotech CRO

Flexible Partnerships That Scale With Your Program

Immunology programs supported through our Full-Service CRO model or via embedded specialist resource through FSP Solutions, providing sponsors with the flexibility to scale expertise as program requirements and program evolution demand.

Full-Service CRO

Delivering Global Immunology Programs With Confidence

Established global site networks and multinational operational expertise enable sponsors to coordinate international immunology programs through established investigator networks and coordinated international program leadership.

Global CRO

Scalable Embedded Immunology Expertise

Dedicated immunology specialists available through FSP Solutions, providing experienced CRAs, trial managers and scientific professionals embedded within sponsor teams as scalable embedded immunology expertise aligned with sponsor requirements.

FSP Solutions
Biotech CRO

Immunology CRO Support for Biotech Companies

Biotechnology companies advancing immunology programs benefit from scalable scientific expertise, biomarker leadership and long-term collaborative partnership throughout development. Integrated scientific understanding across autoimmune disease, biologics, immuno-oncology and advanced therapies supports confident program delivery at every stage.

Evestia Clinical provides integrated scientific partnership supporting immunology programs from Phase I through registration. Available through our Full-Service CRO model or embedded FSP specialists, and structured as a dedicated Biotech CRO, the partnership adapts as programs evolve and priorities change.

FAQs

Frequently Asked Questions About Immunology CRO Services

Partner With Us

Helping Immunology Innovators Develop Transformative Therapies

Biomarker-driven development, integrated scientific expertise and collaborative partnership from first-in-human studies to global registration. Evestia Clinical supports biotechnology and pharmaceutical companies advancing autoimmune, immuno-oncology, biologics and advanced immune-based programs with the scientific depth and delivery that successful immunology development requires.